Brazil: These 45 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024
DrugPatentWatch® Estimated Loss of Exclusivity Dates in Brazil
The content of this page is licensed under a Creative Commons Attribution 4.0 International License.
Generic Entry Dates in Other Countries
Friedman, Yali, "Brazil: These 45 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024" DrugPatentWatch.com thinkBiotech, 2023 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ILEVRO (nepafenac) generic drug versions launch?
Generic name: nepafenac
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2023
Generic Entry Controlled by: Brazil Patent PI0411361
Patent Title: composições oftálmicas contendo uma combinação sinérgica de dois polìmeros
This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO
See drug price trends for ILEVRO.
The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.
When can JANUMET (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Brazil Patent PI0411726
Patent Title: composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
This drug has one hundred and thirty-six patent family members in forty-six countries. There has been litigation on patents covering JANUMET
See drug price trends for JANUMET.
The generic ingredient in JANUMET is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUMET XR (metformin hydrochloride; sitagliptin phosphate) generic drug versions launch?
Generic name: metformin hydrochloride; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Brazil Patent PI0411726
Patent Title: composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUMET XR
See drug price trends for JANUMET XR.
The generic ingredient in JANUMET XR is metformin hydrochloride; sitagliptin phosphate. There are forty-nine drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the metformin hydrochloride; sitagliptin phosphate profile page.
When can JANUVIA (sitagliptin phosphate) generic drug versions launch?
Generic name: sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Brazil Patent PI0411726
Patent Title: composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JANUVIA
See drug price trends for JANUVIA.
The generic ingredient in JANUVIA is sitagliptin phosphate. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the sitagliptin phosphate profile page.
When can JUVISYNC (simvastatin; sitagliptin phosphate) generic drug versions launch?
Generic name: simvastatin; sitagliptin phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 24, 2023
Generic Entry Controlled by: Brazil Patent PI0411726
Patent Title: composto, monoidrato, sal, composição farmacêutica, método para o tratamento de diabetes tipo 2, processo para preparar o composto, uso do composto, e, processo para a preparação do monoidrato cristalino
JUVISYNC is a drug marketed by Merck Sharp Dohme. There are four patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and twenty-seven patent family members in forty-six countries. There has been litigation on patents covering JUVISYNC
The generic ingredient in JUVISYNC is simvastatin; sitagliptin phosphate. There are forty drug master file entries for this API. Additional details are available on the simvastatin; sitagliptin phosphate profile page.
When can ORIAHNN (COPACKAGED) (elagolix sodium,estradiol,norethindrone acetate; elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Brazil Patent PI0412314
Patent Title: derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
ORIAHNN (COPACKAGED) is a drug marketed by Abbvie Inc. There are five patents protecting this drug.
This drug has thirty-eight patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)
The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.
When can ORILISSA (elagolix sodium) generic drug versions launch?
Generic name: elagolix sodium
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2023
Generic Entry Controlled by: Brazil Patent PI0412314
Patent Title: derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
This drug has forty-three patent family members in twenty-four countries. There has been litigation on patents covering ORILISSA
See drug price trends for ORILISSA.
The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.
When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch?
Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2023
Generic Entry Controlled by: Brazil Patent PI0413283
Patent Title: derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering VRAYLAR
See drug price trends for VRAYLAR.
The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the cariprazine hydrochloride profile page.
When can RYZODEG 70/30 (insulin aspart; insulin degludec) generic drug versions launch?
Generic name: insulin aspart; insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Brazil Patent PI0413276
Patent Title: derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente
RYZODEG 70/30 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering RYZODEG 70/30
The generic ingredient in RYZODEG 70/30 is insulin aspart; insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin aspart; insulin degludec profile page.
When can TRESIBA (insulin degludec) generic drug versions launch?
Generic name: insulin degludec
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Brazil Patent PI0413276
Patent Title: derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering TRESIBA
See drug price trends for TRESIBA.
The generic ingredient in TRESIBA is insulin degludec. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec profile page.
When can XULTOPHY 100/3.6 (insulin degludec; liraglutide) generic drug versions launch?
Generic name: insulin degludec; liraglutide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 05, 2023
Generic Entry Controlled by: Brazil Patent PI0413276
Patent Title: derivado de insulina, complexo de zinco do mesmo, composição farmacêutica, e, método para tratar diabete em um paciente
XULTOPHY 100/3.6 is a drug marketed by
This drug has one hundred and twenty patent family members in forty-two countries. There has been litigation on patents covering XULTOPHY 100/3.6
The generic ingredient in XULTOPHY 100/3.6 is insulin degludec; liraglutide. There are forty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the insulin degludec; liraglutide profile page.
When can PRADAXA (dabigatran etexilate mesylate) generic drug versions launch?
Generic name: dabigatran etexilate mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 29, 2023
Generic Entry Controlled by: Brazil Patent PI0413849
Patent Title: metanossulfonato de etiléster de ácido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamin o]-metil}-1-metil-1h-benzimidazol-5-carbonil)-piridin-2 -il-amino]-propiÈnico e seu uso como medicamento
This drug has two hundred and sixty-eight patent family members in fifty-two countries. There has been litigation on patents covering PRADAXA
See drug price trends for PRADAXA.
The generic ingredient in PRADAXA is dabigatran etexilate mesylate. There are twenty-six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the dabigatran etexilate mesylate profile page.
When can JEVTANA KIT (cabazitaxel) generic drug versions launch?
Generic name: cabazitaxel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: September 19, 2023
Generic Entry Controlled by: Brazil Patent PI0414492
Patent Title: solvato acetÈnico do dimetóxi docetaxel e seu processo de preparação
JEVTANA KIT is a drug marketed by Sanofi Aventis Us. There are four patents protecting this drug. Three tentatively approved generics are ready to enter the market.
This drug has ninety-six patent family members in forty-six countries. There has been litigation on patents covering JEVTANA KIT
The generic ingredient in JEVTANA KIT is cabazitaxel. There are thirteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cabazitaxel profile page.
When can VIBATIV (telavancin hydrochloride) generic drug versions launch?
Generic name: telavancin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 22, 2023
Generic Entry Controlled by: Brazil Patent PI0415853
Patent Title: sal de cloridreto de telavancina, processo para preparar um sal de cloridreto de telavancina e produto
VIBATIV is a drug marketed by Cumberland Pharms. There are three patents protecting this drug.
This drug has one hundred and twenty-eight patent family members in thirty-five countries.
See drug price trends for VIBATIV.
The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.
When can DUETACT (glimepiride; pioglitazone hydrochloride) generic drug versions launch?
Generic name: glimepiride; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 31, 2023
Generic Entry Controlled by: Brazil Patent PI0414979
Patent Title: preparação sólida
DUETACT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has fifty-nine patent family members in thirty-one countries. There has been litigation on patents covering DUETACT
See drug price trends for DUETACT.
The generic ingredient in DUETACT is glimepiride; pioglitazone hydrochloride. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the glimepiride; pioglitazone hydrochloride profile page.
When can KUVAN (sapropterin dihydrochloride) generic drug versions launch?
Generic name: sapropterin dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 17, 2023
Generic Entry Controlled by: Brazil Patent PI0416566
Patent Title: tratamento de fenilcetonúrias com bh4
KUVAN is a drug marketed by Biomarin Pharm. There are ten patents protecting this drug and three Paragraph IV challenges.
This drug has one hundred and fourteen patent family members in twenty-six countries. There has been litigation on patents covering KUVAN
See drug price trends for KUVAN.
The generic ingredient in KUVAN is sapropterin dihydrochloride. There are three drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the sapropterin dihydrochloride profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: Brazil Patent 122,014,001,142
Patent Title: Formulação purgativa colônica, kit, método de purgar o cólon de um paciente, e, processo de produzir a formulação purgativa colônica
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) generic drug versions launch?
Generic name: sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 19, 2023
Generic Entry Controlled by: Brazil Patent PI0416702
Patent Title: FORMULAÇÃO PURGATIVA COLÔNICA, KIT, MÉTODOS DE PURGAR O CÓLON DE UM PACIENTE, DE TRATAR UM PACIENTE COM, OU SUSCETÍVEL A, UM DISTÚRBIO GASTROINTESTINAL, E DE TRATAR UM PACIENTE SOFRENDO DE, OU SUSCETÍVEL À, CONSTIPAÇÃO, E, PROCESSO DE PRODUZIR A FORMULAÇÃO PURGATIVA COLÔNICA
OSMOPREP is a drug marketed by Salix Pharms. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has twenty-nine patent family members in eleven countries.
See drug price trends for OSMOPREP.
The generic ingredient in OSMOPREP is sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate. There are one thousand four hundred and seventy-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate profile page.
When can SAXENDA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Brazil Patent PI0416743
Patent Title: formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
This drug has two hundred and ninety-nine patent family members in thirty-two countries. There has been litigation on patents covering SAXENDA
See drug price trends for SAXENDA.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can VICTOZA (liraglutide recombinant) generic drug versions launch?
Generic name: liraglutide recombinant
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2023
Generic Entry Controlled by: Brazil Patent PI0416743
Patent Title: formulação farmacêutica, e, métodos de preparar uma formulação de peptìdeo apropriada para uso em um dispositivo de injeção, para reduzir depósitos em equipamento de produção e no produto final, e para reduzir o entupimento de dispositivos de injeção por uma formulação de peptìdeo
This drug has one hundred and ninety-seven patent family members in thirty-two countries. There has been litigation on patents covering VICTOZA
See drug price trends for VICTOZA.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the liraglutide recombinant profile page.
When can XARELTO (rivaroxaban) generic drug versions launch?
Generic name: rivaroxaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2023
Generic Entry Controlled by: Brazil Patent PI0416404
Patent Title: processo para a preparação de uma composição farmacêutica sólida, aplicável por via oral
This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO
See drug price trends for XARELTO.
The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.
When can VYZULTA (latanoprostene bunod) generic drug versions launch?
Generic name: latanoprostene bunod
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 05, 2024
Generic Entry Controlled by: Brazil Patent PI0418245
Patent Title: nitróxi-derivados de prostaglandina
This drug has fifty-three patent family members in thirty-eight countries.
See drug price trends for VYZULTA.
The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this generic product. Additional details are available on the latanoprostene bunod profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Brazil Patent PI0518483
Patent Title: composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can NAMZARIC (donepezil hydrochloride; memantine hydrochloride) generic drug versions launch?
Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 29, 2024
Generic Entry Controlled by: Brazil Patent PI0607017
Patent Title: métodos e composições para o tratamento de condições relacionadas ao snc
This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC
See drug price trends for NAMZARIC.
The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.
When can ORKAMBI (ivacaftor; lumacaftor) generic drug versions launch?
Generic name: ivacaftor; lumacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 30, 2024
Generic Entry Controlled by: Brazil Patent PI0507278
Patent Title: moduladores dos transportadores do cassete de ligação ao atp
ORKAMBI is a drug marketed by Vertex Pharms Inc. There are twenty patents protecting this drug.
This drug has four hundred and forty-eight patent family members in thirty-five countries.
See drug price trends for ORKAMBI.
The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ivacaftor; lumacaftor profile page.
When can EPANOVA (omega-3-carboxylic acids) generic drug versions launch?
Generic name: omega-3-carboxylic acids
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 13, 2024
Generic Entry Controlled by: Brazil Patent PI0507473
Patent Title: cápsula de gelatina mole, uso de pelo menos um ácido graxo polinsaturado Èmega-3, processo para a manufatura de uma cápsula de gelatina mole, uso de gelatina extraìda por um processo de extração, e, método de tratamento ou de profilaxia de uma condição
EPANOVA is a drug marketed by Astrazeneca. There are seven patents protecting this drug.
This drug has eighty-four patent family members in forty countries.
The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.
When can OSPHENA (ospemifene) generic drug versions launch?
Generic name: ospemifene
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 23, 2024
Generic Entry Controlled by: Brazil Patent PI0507897
Patent Title: formulação de droga sólida
This drug has ninety-four patent family members in thirty-one countries. There has been litigation on patents covering OSPHENA
See drug price trends for OSPHENA.
The generic ingredient in OSPHENA is ospemifene. There are six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ospemifene profile page.
When can RUKOBIA (fostemsavir tromethamine) generic drug versions launch?
Generic name: fostemsavir tromethamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2024
Generic Entry Controlled by: Brazil Patent PI0508876
Patent Title: pró medicamentos de agentes antivirais de piperazina e piperidina substituìda
RUKOBIA is a drug marketed by Viiv Hlthcare. There are three patents protecting this drug.
This drug has thirty-nine patent family members in thirty countries.
See drug price trends for RUKOBIA.
The generic ingredient in RUKOBIA is fostemsavir tromethamine. One supplier is listed for this generic product. Additional details are available on the fostemsavir tromethamine profile page.
When can SYNJARDY (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Brazil Patent PI0508830
Patent Title: derivados de benzeno substituìdos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
This drug has one hundred and ninety-two patent family members in forty-four countries. There has been litigation on patents covering SYNJARDY
See drug price trends for SYNJARDY.
The generic ingredient in SYNJARDY is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can SYNJARDY XR (empagliflozin; metformin hydrochloride) generic drug versions launch?
Generic name: empagliflozin; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 16, 2024
Generic Entry Controlled by: Brazil Patent PI0508830
Patent Title: derivados de benzeno substituìdos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
This drug has one hundred and sixty-six patent family members in forty countries. There has been litigation on patents covering SYNJARDY XR
See drug price trends for SYNJARDY XR.
The generic ingredient in SYNJARDY XR is empagliflozin; metformin hydrochloride. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; metformin hydrochloride profile page.
When can TEKTURNA (aliskiren hemifumarate) generic drug versions launch?
Generic name: aliskiren hemifumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 17, 2024
Generic Entry Controlled by: Brazil Patent PI0508833
Patent Title: formulações galênicas de compostos orgánicos
This drug has forty patent family members in twenty-two countries. There has been litigation on patents covering TEKTURNA
See drug price trends for TEKTURNA.
The generic ingredient in TEKTURNA is aliskiren hemifumarate. There are four drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aliskiren hemifumarate profile page.
When can IMPLANON (etonogestrel) generic drug versions launch?
Generic name: etonogestrel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 19, 2024
Generic Entry Controlled by: Brazil Patent PI0508865
Patent Title: dispositivo de liberação de medicamento visìvel por raio x
IMPLANON is a drug marketed by Organon. There is one patent protecting this drug.
This drug has thirty-two patent family members in twenty-six countries.
The generic ingredient in IMPLANON is etonogestrel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the etonogestrel profile page.
When can FORTEO (teriparatide recombinant human) generic drug versions launch?
Generic name: teriparatide recombinant human
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 30, 2024
Generic Entry Controlled by: Brazil Patent PI0509269
Patent Title: aparelho de dispensação de medicamento
This drug has thirty-seven patent family members in twenty-five countries. There has been litigation on patents covering FORTEO
See drug price trends for FORTEO.
The generic ingredient in FORTEO is teriparatide recombinant human. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the teriparatide recombinant human profile page.
When can DUAVEE (bazedoxifene acetate; estrogens, conjugated) generic drug versions launch?
Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 07, 2024
Generic Entry Controlled by: Brazil Patent PI0509191
Patent Title: polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno
This drug has twenty-two patent family members in twenty countries.
See drug price trends for DUAVEE.
The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.
When can NATAZIA (dienogest; estradiol valerate) generic drug versions launch?
Generic name: dienogest; estradiol valerate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 20, 2024
Generic Entry Controlled by: Brazil Patent PI0510005
Patent Title: preparação contraceptiva multifase baseada em estrogênio natural com um gestagênio sintético
This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA
See drug price trends for NATAZIA.
The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.
When can INCRUSE ELLIPTA (umeclidinium bromide) generic drug versions launch?
Generic name: umeclidinium bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 27, 2024
Generic Entry Controlled by: Brazil Patent PI0510170
Patent Title: antagonistas do receptor muscarìnico de acetilcolina
This drug has one hundred and seventy-seven patent family members in thirty-nine countries.
See drug price trends for INCRUSE ELLIPTA .
The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the umeclidinium bromide profile page.
When can VIZIMPRO (dacomitinib) generic drug versions launch?
Generic name: dacomitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 06, 2024
Generic Entry Controlled by: Brazil Patent PI0510604
Patent Title: 4-fenilamino-quinazolin-6-il-amidas
VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.
This drug has ninety patent family members in forty-seven countries.
See drug price trends for VIZIMPRO.
The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.
When can KYPROLIS (carfilzomib) generic drug versions launch?
Generic name: carfilzomib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 10, 2024
Generic Entry Controlled by: Brazil Patent PI0510802
Patent Title: compostos para inibição de enzima
KYPROLIS is a drug marketed by Onyx Therap. There are twelve patents protecting this drug and three Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.
This drug has two hundred and nineteen patent family members in forty-one countries. There has been litigation on patents covering KYPROLIS
See drug price trends for KYPROLIS.
The generic ingredient in KYPROLIS is carfilzomib. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the carfilzomib profile page.
When can ARCAPTA NEOHALER (indacaterol maleate) generic drug versions launch?
Generic name: indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Brazil Patent PI0511073
Patent Title: dispositivo inalador
This drug has eighty-six patent family members in thirty-nine countries. There has been litigation on patents covering ARCAPTA NEOHALER
See drug price trends for ARCAPTA NEOHALER.
The generic ingredient in ARCAPTA NEOHALER is indacaterol maleate. Additional details are available on the indacaterol maleate profile page.
When can UTIBRON (glycopyrrolate ; indacaterol maleate) generic drug versions launch?
Generic name: glycopyrrolate ; indacaterol maleate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 13, 2024
Generic Entry Controlled by: Brazil Patent PI0511073
Patent Title: dispositivo inalador
UTIBRON is a drug marketed by Novartis. There are three patents protecting this drug.
This drug has one hundred and forty-eight patent family members in forty countries. There has been litigation on patents covering UTIBRON
See drug price trends for UTIBRON.
The generic ingredient in UTIBRON is glycopyrrolate ; indacaterol maleate. There are seventeen drug master file entries for this API. Additional details are available on the glycopyrrolate ; indacaterol maleate profile page.
When can VITEKTA (elvitegravir) generic drug versions launch?
Generic name: elvitegravir
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: Brazil Patent PI0510114
Patent Title: cristal estável de composto 4-oxoquinolina
VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug.
This drug has eighty-three patent family members in thirty-five countries. There has been litigation on patents covering VITEKTA
The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.
When can CAPRELSA (vandetanib) generic drug versions launch?
Generic name: vandetanib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 21, 2024
Generic Entry Controlled by: Brazil Patent PI0511253
Patent Title: composição farmacêutica
CAPRELSA is a drug marketed by Genzyme Corp. There are three patents protecting this drug.
This drug has one hundred and forty-two patent family members in forty-three countries.
See drug price trends for CAPRELSA.
The generic ingredient in CAPRELSA is vandetanib. One supplier is listed for this generic product. Additional details are available on the vandetanib profile page.
When can KOMBIGLYZE XR (metformin hydrochloride; saxagliptin hydrochloride) generic drug versions launch?
Generic name: metformin hydrochloride; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Brazil Patent PI0510419
Patent Title: formulação e método de comprimido revestido
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering KOMBIGLYZE XR
See drug price trends for KOMBIGLYZE XR.
The generic ingredient in KOMBIGLYZE XR is metformin hydrochloride; saxagliptin hydrochloride. There are forty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the metformin hydrochloride; saxagliptin hydrochloride profile page.
When can ONGLYZA (saxagliptin hydrochloride) generic drug versions launch?
Generic name: saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 28, 2024
Generic Entry Controlled by: Brazil Patent PI0510419
Patent Title: formulação e método de comprimido revestido
This drug has one hundred and twenty-seven patent family members in forty-one countries. There has been litigation on patents covering ONGLYZA
See drug price trends for ONGLYZA.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the saxagliptin hydrochloride profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Brazil Patent 122,018,014,454
Patent Title: forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
This drug has eighty-three patent family members in thirty-four countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Brazil Patent PI0512792
Patent Title: formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol
This drug has eighty-three patent family members in thirty-four countries. There has been litigation on patents covering NUCYNTA
See drug price trends for NUCYNTA.
The generic ingredient in NUCYNTA is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Brazil Patent 122,018,014,454
Patent Title: forma cristalina sólida a do cloridrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
This drug has three hundred and fifty-two patent family members in thirty-seven countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can NUCYNTA ER (tapentadol hydrochloride) generic drug versions launch?
Generic name: tapentadol hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2024
Generic Entry Controlled by: Brazil Patent PI0512792
Patent Title: formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol
This drug has three hundred and fifty-two patent family members in thirty-seven countries. There has been litigation on patents covering NUCYNTA ER
See drug price trends for NUCYNTA ER.
The generic ingredient in NUCYNTA ER is tapentadol hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the tapentadol hydrochloride profile page.
When can FYCOMPA (perampanel) generic drug versions launch?
Generic name: perampanel
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 06, 2024
Generic Entry Controlled by: Brazil Patent PI0510254
Patent Title: cristal de composto de 1,2-diidropiridina e método para produzir o mesmo
This drug has one hundred and one patent family members in thirty-three countries.
See drug price trends for FYCOMPA.
The generic ingredient in FYCOMPA is perampanel. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the perampanel profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:






Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.